Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more
Market Cap & Net Worth: Sakar Healthcare Limited (SAKAR)
Sakar Healthcare Limited (NSE:SAKAR) has a market capitalization of $138.27 Million (₹11.97 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #23463 globally and #1216 in its home market, demonstrating a 3.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sakar Healthcare Limited's stock price ₹545.55 by its total outstanding shares 21949910 (21.95 Million).
Sakar Healthcare Limited Market Cap History: 2017 to 2026
Sakar Healthcare Limited's market capitalization history from 2017 to 2026. Data shows growth from $15.71 Million to $138.27 Million (28.50% CAGR).
Sakar Healthcare Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sakar Healthcare Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Sakar Healthcare Limited's market cap is 0.06 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.59x
Sakar Healthcare Limited's market cap is 0.59 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $15.71 Million | $441.71 Million | $33.78 Million | 0.04x | 0.47x |
| 2018 | $15.08 Million | $530.77 Million | $38.15 Million | 0.03x | 0.40x |
| 2019 | $16.98 Million | $682.49 Million | $70.11 Million | 0.02x | 0.24x |
| 2020 | $24.90 Million | $829.80 Million | $96.23 Million | 0.03x | 0.26x |
| 2021 | $41.22 Million | $947.39 Million | $106.83 Million | 0.04x | 0.39x |
| 2022 | $56.84 Million | $1.28 Billion | $152.43 Million | 0.04x | 0.37x |
| 2023 | $101.39 Million | $1.33 Billion | $127.59 Million | 0.08x | 0.79x |
| 2024 | $75.14 Million | $1.54 Billion | $116.71 Million | 0.05x | 0.64x |
| 2025 | $103.71 Million | $1.78 Billion | $175.02 Million | 0.06x | 0.59x |
Competitor Companies of SAKAR by Market Capitalization
Companies near Sakar Healthcare Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Sakar Healthcare Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Sakar Healthcare Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, Sakar Healthcare Limited's market cap moved from $15.71 Million to $ 138.27 Million, with a yearly change of 28.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹138.27 Million | +33.32% |
| 2025 | ₹103.71 Million | +38.03% |
| 2024 | ₹75.14 Million | -25.90% |
| 2023 | ₹101.39 Million | +78.39% |
| 2022 | ₹56.84 Million | +37.87% |
| 2021 | ₹41.22 Million | +65.55% |
| 2020 | ₹24.90 Million | +46.64% |
| 2019 | ₹16.98 Million | +12.61% |
| 2018 | ₹15.08 Million | -4.03% |
| 2017 | ₹15.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sakar Healthcare Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.27 Million USD |
| MoneyControl | $138.27 Million USD |
| MarketWatch | $138.27 Million USD |
| marketcap.company | $138.27 Million USD |
| Reuters | $138.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.